Neurogene (NGNE) Other Operating Expenses (2013 - 2019)

Neurogene (NGNE) reported Other Operating Expenses of $4.9 million for Q4 2019, down 90.05% quarter-over-quarter from $49.1 million in Q3 2019.

Neurogene (NGNE) Other Operating Expenses (2013 - 2019) Analysis & Trends

Neurogene has reported Other Operating Expenses for 3 years, with the latest figure at $4.9 million in Q4 2019.

For the quarter ending Q4 2019, Other Operating Expenses changed N/A year-over-year to $4.9 million; the trailing twelve-month figure through Sep 2020 stood at $4.9 million (down 89.63% YoY), and the FY2019 full-year result was $47.7 million, changed N/A from the prior year.
Other Operating Expenses for Q4 2019 stood at $4.9 million, down from $49.1 million in the prior quarter.
The five-year high for Other Operating Expenses was $49.1 million in Q3 2019, with the low at -$2.0 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Neurogene	216.17 Mn	216.17 Mn	-

Download Data